Patent ID: 8871189

Claim:
A targeted delivery composition, comprising: (a) a nanocarrier including a therapeutic or diagnostic agent or a combination thereof; and (b) a conjugate having the formula: A-(LPEG)-MMP i ; wherein, A is an attachment component for attaching said conjugate to said nanocarrier; (LPEG) is selected from: (i) a linking group having a linear assembly of from 1 to 3 polyethylene glycol components, (ii) a linking group having the formula [(EG)(P)] m wherein each EG is an ethylene glycol group independently selected from the group consisting of triethylene glycol, tetraethylene glycol, pentaethylene glycol, hexaethylene glycol, heptaethylene glycol and octaethylene glycol, P is a phosphoryl or thiophosphoryl group, and m is an integer of from 1 to 20; or (iii) a linking group having the formula —Z 1 —Z 2 —Z 3 —, wherein Z 1 and Z 3 are independently selected from the group consisting of a PEG component having a defined length and W n , wherein W is an amino acid and the subscript n is an integer from 0 to 3; and Z 2 is selected from the group consisting of a PEG component having a defined length and a coupling group selected from an amide, thioamide, ester, carbamate or urea for connecting Z 1 and Z 3 ; and MMP i is a MMP enzyme inhibitor having the formula: wherein X is a member selected from the group consisting of O and S; Y is a member selected from the group consisting of pyridyl and phenyl, wherein said phenyl is optionally substituted with OH, OCH 3 , OCF 3 and CH 3 ; and the wavy line indicates the point of attachment to (LPEG).